marked.bio

Company

Cullinan Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

zipalertinib 1pembrolizumab 1datopotamab deruxtecan 1

Trials

2 of 2 trials shown

  1. A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

    Active, not recruiting Phase 1/2 Cullinan Therapeutics Started 2019Primary completion 2025-10 NCT04036682

    zipalertinib

    Documented EGFR ex20ins mutation demonstrated by a validated test listed in Section 9.7 and performed in a Clinic…

    EGFR exon 20 insertionNon Small Cell Lung Cancer, EGFR Exon 20 Mutation

  2. A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

    Active, not recruiting Phase 1 Cullinan Therapeutics Started 2021Primary completion 2026-03 NCT05117476

    CLN-619pembrolizumabpaclitaxelcarboplatinpemetrexeddatopotamab deruxtecan FDA

    …1: Histologically or cytologically confirmed metastatic or locally advanced, unresectable EGFRm NSCLC.

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor, NSCLC